These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

686 related items for PubMed ID: 23082811

  • 1. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
    Leman J, Burden AD.
    Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
    [Abstract] [Full Text] [Related]

  • 2. Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?
    Langley RG.
    J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():21-9. PubMed ID: 22356632
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Anti-TNF agents for the treatment of psoriasis.
    Kircik LH, Del Rosso JQ.
    J Drugs Dermatol; 2009 Jun; 8(6):546-59. PubMed ID: 19537380
    [Abstract] [Full Text] [Related]

  • 6. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris.
    Gniadecki R, Bang B, Bryld LE, Iversen L, Lasthein S, Skov L.
    Br J Dermatol; 2015 Jan; 172(1):244-52. PubMed ID: 25132294
    [Abstract] [Full Text] [Related]

  • 7. Switching biologics for psoriasis.
    Ormerod AD.
    Br J Dermatol; 2010 Oct; 163(4):667-9. PubMed ID: 20854399
    [No Abstract] [Full Text] [Related]

  • 8. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
    Van Lümig PP, Lecluse LL, Driessen RJ, Spuls PI, Boezeman JB, van de Kerkhof PC, De Jong EM.
    Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
    [Abstract] [Full Text] [Related]

  • 9. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
    Vender R.
    J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
    [Abstract] [Full Text] [Related]

  • 10. The evolving role of biologics in the treatment of pediatric psoriasis.
    Luu M, Cordoro KM.
    Skin Therapy Lett; 2013 Feb; 18(2):1-4. PubMed ID: 23508772
    [Abstract] [Full Text] [Related]

  • 11. Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis.
    Ferrándiz C, García A, Blasco AJ, Lázaro P.
    J Eur Acad Dermatol Venereol; 2012 Jun; 26(6):768-77. PubMed ID: 22126264
    [Abstract] [Full Text] [Related]

  • 12. Tumor necrosis factor antagonists in the therapy of psoriasis.
    Mössner R, Schön MP, Reich K.
    Clin Dermatol; 2008 Jun; 26(5):486-502. PubMed ID: 18755367
    [Abstract] [Full Text] [Related]

  • 13. Biological agents in the treatment of psoriasis.
    Tzu J, Krulig E, Cardenas V, Kerdel FA.
    G Ital Dermatol Venereol; 2008 Oct; 143(5):315-27. PubMed ID: 18833073
    [Abstract] [Full Text] [Related]

  • 14. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
    Woolf RT, Smith CH, Robertson K, Barker JN.
    Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
    [No Abstract] [Full Text] [Related]

  • 15. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.
    Mössner R, Reich K.
    Curr Probl Dermatol; 2009 Oct; 38():107-136. PubMed ID: 19710553
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study.
    Viguier M, Pagès C, Aubin F, Delaporte E, Descamps V, Lok C, Beylot-Barry M, Séneschal J, Dubertret L, Morand JJ, Dréno B, Bachelez H, Groupe Français de Recherche sur le Psoriasis.
    Br J Dermatol; 2012 Aug; 167(2):417-23. PubMed ID: 22413927
    [Abstract] [Full Text] [Related]

  • 17. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data.
    Rustin MH.
    Br J Dermatol; 2012 Nov; 167 Suppl 3():3-11. PubMed ID: 23082810
    [Abstract] [Full Text] [Related]

  • 18. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
    Gniadecki R, Kragballe K, Dam TN, Skov L.
    Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
    [Abstract] [Full Text] [Related]

  • 19. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
    Weinberg JM, Saini R.
    Cutis; 2003 Jan; 71(1):25-9. PubMed ID: 12553627
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis.
    Uhlenhake EE, Feldman SR.
    Expert Opin Biol Ther; 2010 Jul; 10(7):1105-12. PubMed ID: 20446825
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.